Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
J Acquir Immune Defic Syndr ; 69(2): e74-81, 2015 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-26009838

RESUMO

OBJECTIVE: To examine the uptake of services and behaviors in the prevention of mother-to-child HIV transmission (PMTCT) cascade in Zimbabwe and to determine factors associated with MTCT and maternal antiretroviral therapy (ART) or antiretroviral (ARV) prophylaxis. DESIGN: Analysis of cross-sectional data from mother-infant pairs. METHODS: We analyzed baseline data collected in 2012 as part of the impact evaluation of Zimbabwe's Accelerated National PMTCT Program. Using multistage cluster sampling, eligible mother-infant pairs were randomly sampled from the catchment areas of 157 facilities in 5 provinces, tested for HIV infection, and interviewed about PMTCT service utilization. RESULTS: Of 8800 women, 94% attended ≥ 1 antenatal care visit, 92% knew their HIV serostatus during pregnancy, 77% delivered in a health facility, and 92% attended the 6-8 week postnatal visit. Among 1075 (12%) HIV-infected women, 59% reported ART/ARV prophylaxis and 63% of their HIV-exposed infants received ARV prophylaxis. Among HIV-exposed infants, maternal receipt of ART/ARV prophylaxis was protective against MTCT [adjusted prevalence ratio (PR(a)): 0.41, 95% confidence interval (CI): 0.23 to 0.74]. Factors associated with receipt of maternal ART/ARV prophylaxis included ≥ 4 antenatal care visits (PR(a): 1.18, 95% CI: 1.01 to 1.38), institutional delivery (PR(a): 1.31, 95% CI: 1.13 to 1.52), and disclosure of serostatus (PRa: 1.30, 95% CI: 1.12 to 1.49). CONCLUSIONS: These data from women in the community indicate gaps in the PMTCT cascade before the accelerated program, which may have been missed by examination of health facility data alone. These gaps were especially noteworthy for services targeted specifically to HIV-infected women and their infants, such as maternal and infant ART/ARV prophylaxis.


Assuntos
Infecções por HIV/tratamento farmacológico , Infecções por HIV/prevenção & controle , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Aceitação pelo Paciente de Cuidados de Saúde , Complicações Infecciosas na Gravidez/tratamento farmacológico , Administração em Saúde Pública/métodos , Adolescente , Adulto , Antirretrovirais/uso terapêutico , Quimioprevenção/métodos , Estudos Transversais , Coleta de Dados , Feminino , Humanos , Lactente , Recém-Nascido , Gravidez , Adulto Jovem , Zimbábue
2.
J Acquir Immune Defic Syndr ; 63(2): e56-63, 2013 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-23403860

RESUMO

BACKGROUND: The authors piloted an HIV testing and counseling (HTC) approach using respondent-driven sampling (RDS), financial incentives, and persons living with HIV infection (PLHIV). METHODS: Eligible participants were aged 30-60 years, African American or black, and residents of Oakland, CA. Participants were tested for HIV infection and asked to refer up to 3 others. The authors compared the efficiency of RDS to conventional outreach-based HTC with the number needed to screen (NNS). They evaluated the effect of 2 randomly allocated recruitment incentives on the enrollment of high-risk or HIV-positive network associates: a flat incentive ($20) for eligible recruits or a conditional incentive ($10-35) for eligible recruits in priority groups, such as first-time testers. RESULTS: Forty-eight participants (10 PLHIV and 38 HIV negative) initiated recruitment chains resulting in 243 network associates. Nine (3.7%) participants tested HIV positive, of whom 7 (78%) were previously recognized. RDS was more efficient than conventional HTC at identifying any PLHIV (new or previously recognized; RDS: NNS = 27, 95% CI: 14 to 59; conventional: NNS = 154, 95% CI: 95 to 270). There was no difference between the 2 incentive groups in the likelihood of recruiting at least 1 high-risk HIV-negative or HIV-positive network associate (adjusted odds ratio = 0.89, 95% CI: 0.06 to 13.06) or in total number of high-risk HIV-negative or HIV-positive associates (adjusted odds ratio = 0.79, 95% CI: 0.23 to 2.71). CONCLUSIONS: Social network HTC strategies may increase demand for HTC and efficiently identify PLHIV. The flat incentive was as successful as the conditional incentive for recruiting high-risk individuals. Unexpectedly, this method also reidentified PLHIV aware of their status.


Assuntos
Sorodiagnóstico da AIDS , Aconselhamento/economia , Infecções por HIV/diagnóstico , Adulto , Diagnóstico Precoce , Feminino , Soropositividade para HIV , Humanos , Masculino , Programas de Rastreamento , Pessoa de Meia-Idade , Motivação , Seleção de Pacientes , Grupo Associado
3.
Curr Opin HIV AIDS ; 5(3): 232-6, 2010 May.
Artigo em Inglês | MEDLINE | ID: mdl-20539079

RESUMO

PURPOSE OF REVIEW: Increasing demand for HIV treatment and limited resource availability will require the optimization of treatment programming to not only improve individual treatment outcomes, but also to maximize overall benefit for available resources. RECENT FINDINGS: Available research, although recognizing the importance of ensuring or improving treatment adherence, largely focuses on patient barriers or incentives. More research is necessary to examine how decisions made at all levels of treatment programming affect treatment outcomes. SUMMARY: Explicit decisions regarding treatment access, initiation, drug combinations, and potential termination of treatment along with addressing incentives and barriers to treatment adherence are necessary to maximize the overall benefit for available resources. This factor will depend on the involvement of the three main treatment actors, program managers, health practitioners, and patients.


Assuntos
Fármacos Anti-HIV/economia , Fármacos Anti-HIV/uso terapêutico , Terapia Antirretroviral de Alta Atividade/economia , Terapia Antirretroviral de Alta Atividade/métodos , Infecções por HIV/tratamento farmacológico , Infecções por HIV/economia , Política de Saúde , Análise Custo-Benefício , Infecções por HIV/diagnóstico , Infecções por HIV/prevenção & controle , Acessibilidade aos Serviços de Saúde/estatística & dados numéricos , Humanos , Adesão à Medicação/estatística & dados numéricos , Aceitação pelo Paciente de Cuidados de Saúde/estatística & dados numéricos , Resultado do Tratamento
5.
Health Aff (Millwood) ; 28(6): 1578-90, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19887400

RESUMO

AIDS continues to outpace the science, financing, prevention, and treatment efforts of the past quarter-century. There have been different epochs along the evolutionary timeline of the global AIDS response, from the discovery of HIV to the threat posed by the current economic crisis. This timeline serves as a reference to how we have arrived where we are today, in the hope that understanding our past will help us set the course for a more efficient and effective future response.


Assuntos
Síndrome da Imunodeficiência Adquirida/história , Fármacos Anti-HIV/história , Serviços Preventivos de Saúde/tendências , Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Síndrome da Imunodeficiência Adquirida/prevenção & controle , Fármacos Anti-HIV/economia , Custos de Cuidados de Saúde/história , História do Século XX , História do Século XXI , Humanos , Internacionalidade , Serviços Preventivos de Saúde/provisão & distribuição , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...